Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development

|Articles|May 8, 2023

Pharma 2023: New Rules for Clinical Lay Summaries in EU

Estelle Jobson, EUPATI alumna, patient expert and health communications professional discusses changes to the EU's requirements for clinical trial lay summaries.

Estelle Jobson, EUPATI alumna, patient expert and health communications professional discusses changes to the EU's requirements for clinical trial lay summaries at Pharma 2023.

EUPATI offers the following resources for sponsors looking for information on lay summaries:

Patients Involved – Patient feedback on a plain language summary of results

Good Lay Summary Practice – This “Good Lay Summary Practice” is identical to the content of the Good Lay Summary Practice Guidance published on EudraLex, Volume 10, 4 October 2021.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© FlowStudio - © FlowStudio - stock.adobe.com

October 26th, 2026

Measuring What Matters: Realigning Clinical Endpoints with Patient Reality

Patients don’t experience primary endpoints, so trials that stop at biomarkers and rigid rating scales risk declaring success while leaving daily burden untouched, and digital tools only deliver meaningful evidence when they are co-designed with patients and deployed with restraint.

Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health

November 2nd, 2026

Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health

In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.

What Needs to Happen Beyond the Clinical Trial Modernization Act

October 30th, 2026

What Needs to Happen Beyond the Clinical Trial Modernization Act

In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

October 29th, 2026

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.

How Embedding Research Into Routine Community Care Changes Who Gets Access

October 29th, 2026

How Embedding Research Into Routine Community Care Changes Who Gets Access

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.

© putilov_denis - © putilov_denis - stock.adobe.com

October 28th, 2026

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.

What It Would Take to Make Community Trials Accessible and Scalable

October 28th, 2026

What It Would Take to Make Community Trials Accessible and Scalable

In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.

How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?

October 26th, 2026

How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patient cost barriers and site infrastructure challenges must be solved together to close the participation gap in community and rural clinical trials.

Trending on Applied Clinical Trials Online

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions

What Needs to Happen Beyond the Clinical Trial Modernization Act

Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance